CVKD · Cadrenal Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| John Raymond Murphy Director | ▲ Buy | Open Market | 614,792 Shares held | 10/5/2023 | View profile |
| Quang X. Pham CEO and Chairman | ▼ Sell | Open Market | 98,589 Shares held | 6/29/2026 | View profile |
| Glynn Wilson Director | ▼ Sell | Other | 50,000 Shares held | 1/24/2023 | View profile |
| Matthew K. Szot Director | ▼ Sell | Open Market | 0 Shares held | 12/29/2025 | View profile |
Transaction History
| Quang X. Pham | ▼ Sell | Open Market | 7,400 | $22K | 6/29/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 9,029 | $28K | 6/26/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 2,127 | $6K | 6/25/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 2,277 | $7K | 6/23/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 9,167 | $33K | 6/22/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 513 | $2K | 6/17/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 3,613 | $11K | 6/16/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 3,666 | $13K | 6/15/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 12,996 | $51K | 6/12/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 1,462 | $6K | 6/11/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 3,500 | $15K | 6/10/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 12,992 | $53K | 6/9/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 5,893 | $26K | 6/8/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 2,064 | $9K | 6/5/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 3,898 | $17K | 6/4/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 2,323 | $10K | 6/3/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 349 | $2K | 6/2/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 303 | $2K | 5/29/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 2,989 | $15K | 5/28/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 1,165 | $7K | 5/22/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 3,298 | $17K | 5/12/2026 |
| Quang X. Pham | ▼ Sell | Open Market | 6,476 | $37K | 5/11/2026 |
| Matthew K. Szot | ▼ Sell | Open Market | 9,933 | $69K | 12/29/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 1,800 | $25K | 10/27/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 1,315 | $18K | 10/27/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 1,800 | $25K | 10/24/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 1,129 | $16K | 10/24/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 1,800 | $25K | 10/13/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 1,800 | $25K | 10/13/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 1,693 | $24K | 10/9/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 1,800 | $25K | 10/9/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 107 | $1K | 10/6/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 500 | $7K | 10/2/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 1,700 | $24K | 10/1/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 881 | $12K | 10/1/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 100 | $1K | 9/29/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 419 | $6K | 9/29/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 10,900 | $153K | 9/25/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 6,790 | $96K | 9/25/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 1,500 | $21K | 9/24/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 2,581 | $36K | 9/24/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 400 | $6K | 8/28/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 1,193 | $17K | 8/28/2025 |
| Matthew K. Szot | ▼ Sell | Open Market | 1,600 | $22K | 8/27/2025 |
| Quang X. Pham | ▼ Sell | Open Market | 3,836 | $54K | 8/27/2025 |
| Quang X. Pham | ▼ Sell | Gift | 50,000 | $0 | 4/10/2024 |
| Quang X. Pham | ▼ Sell | Gift | 85,000 | $0 | 10/23/2023 |
| John Raymond Murphy | ▲ Buy | Open Market | 2,669 | $2K | 10/5/2023 |
| John Raymond Murphy | ▲ Buy | Open Market | 17,331 | $12K | 10/4/2023 |
| Quang X. Pham | ▲ Buy | Open Market | 20,000 | $18K | 9/5/2023 |
| Quang X. Pham | ▲ Buy | Open Market | 20,000 | $18K | 9/5/2023 |
| Quang X. Pham | ▲ Buy | Open Market | 10,000 | $9K | 9/1/2023 |
| Quang X. Pham | ▲ Buy | Open Market | 20,000 | $19K | 9/1/2023 |
| Quang X. Pham | ▲ Buy | Open Market | 20,000 | $18K | 9/1/2023 |
| Quang X. Pham | ▲ Buy | Open Market | 10,000 | $9K | 9/1/2023 |
| Quang X. Pham | ▲ Buy | Open Market | 10,000 | $8K | 9/1/2023 |
| John Raymond Murphy | ▲ Buy | Open Market | 10,000 | $14K | 3/21/2023 |
| John Raymond Murphy | ▲ Buy | Open Market | 20,000 | $33K | 3/16/2023 |
| Quang X. Pham | ▲ Buy | Grant | 25,000 | $49K | 2/10/2023 |
| Matthew K. Szot | ▲ Buy | Grant | 50,000 | $0 | 1/24/2023 |
| John Raymond Murphy | ▼ Sell | Other | 514,792 | — | 1/24/2023 |
| Glynn Wilson | ▼ Sell | Other | 50,000 | — | 1/24/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cadrenal hires Tungsten Advisors to drive strategic process
Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.
Cadrenal hires Tungsten Advisors to drive strategic process. Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.